Tarsus Pharmaceuticals is set to initiate a Phase 2 study of TP-04 (lotilaner ophthalmic gel) in the second half of 2025 for treating ocular rosacea.

TAHO Pharmaceuticals has begun a Phase III clinical trial in the U.S. for TAH3311, an oral dissolving film (ODF) formulation of apixaban.

TAHO Pharmaceuticals has begun a U.S. Phase III clinical trial for TAH3311, an oral dissolving film (ODF) formulation of apixaban, a direct factor Xa inhibitor.

Tonix Pharmaceuticals has appointed Bradley Raudabaugh as Vice President of Marketing and Errol Gould, Ph.D., as Vice President of Medical Affairs to support the potential launch of TNX-102 SL.

Kiora Pharmaceuticals received IND approval to begin a Phase 2 trial (ABACUS-2) of KIO-301 for vision restoration in retinitis pigmentosa patients.

The National Company Law Tribunal and Department of Pharmaceuticals have granted final approval for the merger of Suven Pharmaceuticals and Cohance Lifesciences, effective May 1, 2025.

MELT-300, a non-IV, non-opioid sublingual tablet, demonstrated positive topline efficacy in a Phase 3 trial for procedural sedation during cataract surgery.

Glenmark Pharmaceuticals has acquired and launched Acetylcysteine Injection (6 gm/30 mL) in the US market, expanding its presence in the hospital segment through the ANDA acquisition from Aspen Pharma USA.

Alys Pharmaceuticals has received FDA IND clearance to initiate a Phase 2a clinical trial for their pioneering genetic medicine program in dermatology, marking a significant milestone in the field.

Phathom Pharmaceuticals presented data at ACG 2024 highlighting VOQUEZNA's efficacy for Non-Erosive GERD, including on-demand use and nocturnal symptom relief.

Tonix Pharmaceuticals has submitted an NDA to the FDA for TNX-102 SL, a non-opioid analgesic, seeking approval for fibromyalgia treatment.

Marinus Pharmaceuticals' Phase 3 TrustTSC trial of oral ganaxolone for tuberous sclerosis complex (TSC)-associated seizures did not meet its primary endpoint.

Crinetics Pharmaceuticals' atumelnant demonstrated significant A4 reductions in a Phase 2 trial, positioning it favorably against existing treatments for congenital adrenal hyperplasia (CAH).

ORIC Pharmaceuticals reported encouraging early data from a Phase 1b trial of ORIC-944 combined with apalutamide in metastatic castration-resistant prostate cancer (mCRPC).

Tonix Pharmaceuticals' TNX-801, a horsepox-based vaccine, demonstrates efficacy in protecting animals against lethal mpox challenge, supporting its potential as a single-dose mpox vaccine.

Hemogenyx Pharmaceuticals has developed a clinical-grade assay to assess FLT3 protein expression in acute myeloid leukemia (AML) cells.

CNS Pharmaceuticals has successfully acquired Orphan Drug Designation from Cortice Biosciences for TPI 287, a novel abeotaxane with potential to cross the blood-brain barrier for treating brain tumors.

Accropeutics' AC-101, a RIPK2 inhibitor, received FDA clearance for a Phase II clinical trial to treat moderate-to-severe Ulcerative Colitis (UC).

• Enanta Pharmaceuticals' Zelicapavir (EDP 938) is in Phase II trials (RSVPEDs and RSVHR) targeting RSV in pediatric and high-risk adult populations. • RSVPEDs, a Phase II trial in RSV-infected children aged 28 days to 3 years, has completed enrollment, with topline data expected in Q4 2024. • EDP-323, another RSV drug candidate from Enanta, showed statistically significant reductions in viral load and clinical symptoms in a Phase IIa human challenge study. • Enanta's financial stability is supported by $272.6 million in cash, cash equivalents, and marketable securities as of June 30, 2024, along with royalties from AbbVie's MAVYRET/MAVIRET.

Alembic Pharmaceuticals has secured final USFDA approval for Pantoprazole Sodium for Injection (40 mg/vial), therapeutically equivalent to Wyeth's Protonix I.V. for Injection.